Cargando…

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types, but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking therapeutic r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleinovink, Jan Willem, Marijt, Koen A., Schoonderwoerd, Mark J. A., van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414865/ https://www.ncbi.nlm.nih.gov/pubmed/28507803 http://dx.doi.org/10.1080/2162402X.2017.1294299

Ejemplares similares

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
por: Fransen, Marieke F., et al.
Publicado: (2021)

A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function
por: Kleinovink, Jan Willem, et al.
Publicado: (2019)

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
por: Sow, Heng Sheng, et al.
Publicado: (2019)

TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019)

Immunogenicity of rat-neu(+) mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment
por: Sow, Heng Sheng, et al.
Publicado: (2020)

Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013)

Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement
por: Marijt, Koen A., et al.
Publicado: (2021)

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines
por: Benonisson, Hreinn, et al.
Publicado: (2018)

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors
por: Scognamiglio, Giosue, et al.
Publicado: (2019)

Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28
por: van Hall, Thorbald, et al.
Publicado: (2000)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy
por: Doorduijn, Elien M., et al.
Publicado: (2017)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling
por: Marijt, Koen A., et al.
Publicado: (2019)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies
por: Rostamian, Somayeh, et al.
Publicado: (2022)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Prerequisites of Colonoscopy
por: Hong, Kyong Hee, et al.
Publicado: (2014)

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
por: van der Sluis, Tetje C., et al.
Publicado: (2023)

Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
por: Martomo, Stella A., et al.
Publicado: (2022)

The Prerequisites of Good Teaching
por: Sachs, Ernest
Publicado: (1952)

Prerequisites for an Artificial Self
por: Hafner, Verena V., et al.
Publicado: (2020)

Efficacy and safety of combination PD‐1/PD‐L1 checkpoint inhibitors for malignant solid tumours: A systematic review
por: Yao, Qigu, et al.
Publicado: (2020)

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
por: van Elsas, Marit, et al.
Publicado: (2020)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

T cell receptor contact to restricting MHC molecules is a prerequisite for peripheral interclonal T cell competition
por: Agenès, Fabien, et al.
Publicado: (2008)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019)

Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies
por: Chung, Chih Kit, et al.
Publicado: (2022)

What’s in a Prerequisite? A Mixed-Methods Approach to Identifying the Impact of a Prerequisite Course
por: Sato, Brian K., et al.
Publicado: (2017)

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication
por: Zom, Gijs G., et al.
Publicado: (2018)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations
por: Beyrend, Guillaume, et al.
Publicado: (2018)

Cationic Nanoparticle-Based Cancer Vaccines
por: Heuts, Jeroen, et al.
Publicado: (2021)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
por: Messeha, Samia S., et al.
Publicado: (2021)

Prerequisites for the Validation of Experiment and Theory
por: Sonnenschein, Lars
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_at3ouhcfb6ida6telgl1ec3i48